Mark your calendars now
Mark your calendars now
The North American Neuro-Ophthalmology Society (NANOS) is dedicated to achieving excellence in care of patients with neuro-ophthalmic diseases by the support and promotion of education, research, and the practice of neuro-ophthalmology.
The NANOS 47th Annual Meeting will deliver a highly interactive, 3D environment. All meeting content can be enjoyed from the comfort of your home or office until March 21st!
Click here to learn more about NANOS.
Click here to view the program.
Click here to view the 2021 Annual Meeting registration fees. Early bird rate expires December 31, 2020. Registration for students and residents is only $50 if you register by December 31, 2020. Students and residents should email proof of their status to email@example.com to receive a coupon code.
Click here to learn more about the NANOS Talent Show.
Telemedicine in neuro-ophthalmology has exponentially grown in adoption in the past year, largely due to the unprecedented changes to medical care necessitated by the COVID-19 pandemic. In this expert panel presentation with Q&A, we will review how telemedicine has impacted neuro-ophthalmology in the COVID era, reflect on the experiences of advantages and pitfalls of using telemedicine for the evaluation and management of neuro-ophthalmic disease, offer practical strategies and resources for the implementation of telemedicine, update attendees on billing and coding in telemedicine, and explore future applications of telemedicine in neuro-ophthalmic care.
Upon completion of this session, participants should be able to: (1) enumerate advantages and pitfalls to telemedicine in clinical practice, and (2) demonstrate clinical examination techniques in telemedicine, and (3) envision practical methods of incorporating telemedicine into individual neuro-ophthalmology practice.
This session is designed to present complex neuro-ophthalmic cases that impact the human visual pathways and ocular motor systems. The format is a clinicopathologic conference. Clinical cases will be presented by neuro-ophthalmologists with comments by a neuroradiologist, neuropathologist and other selected experts. Neuroimaging, laboratory and surgical pathology data will help illustrate clinical point. Cases will be discussed from clinical, anatomic, radiologic and pathologic aspects with emphasis on diagnosis, pathophysiology and management.
Upon completion of this session, participants should be able to: (1) recognize the varied presentations of neuro-ophthalmic disease, (2) correlate the anatomic localization and histopathologic appearance with the clinical presentations, (3) use radiologic procedures in diagnosis effectively (4) recognize both the value and limitations of neuropathology, and (5) discuss newly described diseases and their connection to neuro-ophthalmology.
11:40 am – 12:00 pmCase 6
12:00 pm – 12:20 pm Case 7
12:20 pm – 12:40 pm Case 8
12:40 pm – 1:00 pmCase 9
1:00 pm – 1:20 pmCase 10
1:20 pm – 1:40 pmWrap-up
A variety of infectious agents cause important neuro-ophthalmic disease. Some are old favorites, like syphilis, some are novel and emerging, like COVID-19, and some could even be used as weapons, like botulism. Infectious diseases are commonly on the differential diagnosis with inflammatory etiologies that are best treated with immunosuppressive agents, complicating potential management plans.
Upon completion of this session, participants should be able to: (1) describe the features of multiple neuro-ophthalmic diseases caused by infectious agents, (2) describe management strategies that involve the use of immunosuppressive agents in the setting of known or possible infectious disease, and (3) describe national surveillance and bioterrorism preparedness for botulism.
Everchanging technology affords the continued opportunity to new approaches to evaluation, diagnosis, and treatment strategies. Furthermore, application of artificial intelligence (AI) on big data is one of the most influential revolutions in information technology. In this symposium, we will review current applications of AI in neuro-ophthalmology, advances and diagnostic utility of OCTA, new diagnostic techniques for optic disc drusen, and conclude with novel and current management of two critically important neuro-ophthalmic conditions, NMO and IIH.
Upon completion of this session, participants should be able to: (1) define AI in neuro-ophthalmology, current use, and future impact to create algorithms and make clinical decisions from individual practices to global medicine, (2) discuss clinical applications of OCTA in neuro-ophthalmology, (3) Identify new advances in the diagnosis of optic disc drusen, (4) describe new immunotherapies in NMO, and (5) summarize and evaluate new medical and surgical treatments in IIH.
This session will demonstrate for the neuro-ophthalmologist mechanisms underlying traumatic brain injury (TBI), enumerate the afferent and efferent visual signs and symptoms, and impart knowledge regarding the characteristics of dizziness in the TBI setting. The roles for rehabilitation techniques will also be addressed, as will potential medicolegal issues associated with this condition.
Upon completion of this session, participants should be able to: (1) utilize increased knowledge of the most common afferent and efferent neuro-ophthalmologic signs and symptoms of TBI, (2) use history and examination skills to capture symptoms and signs associated with dizziness in TBI, and (3) demonstrate improved awareness and use of rehabilitation techniques for treatment of neuro-ophthalmologic signs and symptoms of TBI.
5:00 pm – 5:30 pm WIN
5:30 pm – 6:00 pm YONO
6:00 pm – 7:00 pm Social Hour
Cognitive visual disorders result from some of the most common diseases of aging that we encounter, including cerebrovascular and neurodegenerative diseases. This session will review the classification of higher order visual processing, pertinent visual features for common neurodegenerative diseases (i.e. Alzheimer’s disease, Parkinson’s disease, and Lewy Body Dementia), advances that have been made in neuroimaging related to cognitive visual dysfunction, and the future of ophthalmic imaging as a biomarker for diseases impacting visual cognition.
Upon completion of this session, participants should be able to: (1) identify and list higher order visual processing disorders, their associated clinical anatomy and the differential diagnosis, (2) understand available imaging tools to aid in the diagnosis of visual cognitive dysfunction, and (3) provide treatment strategies and management recommendations for visual cognitive dysfunction, specifically acquired disorders for reading.
The management of pediatric neuro-ophthalmologic patients is often controversial. As many pediatric neuro-ophthalmologic conditions are uncommon, sufficient data is often unavailable to provide definitive evidence-based guidelines for diagnostic evaluation and treatment. This symposium will review controversies regarding the management of various pediatric neuro-ophthalmologic entities including papilledema, optic neuritis, vigabatrin toxicity, optic pathway gliomas, and infantile nystagmus syndrome.
Upon completion of this session, participants should be able to: (1) understand which tests are required for the diagnosis of various pediatric neuro-ophthalmologic entities, (2) understand the interpretation of tests that are required for the diagnosis of various pediatric neuro-ophthalmologic entities, and (3) understand the limitations of tests that are required for the diagnosis of various pediatric neuro-ophthalmologic entities.
|Registration Type||Early bird (12/31/20)||Regular (1/1/21 and after)|